First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
Private psychedelics medicine company Beckley Psytech Ltd announced this week that the first patient has been dosed in the second part of its two-part Phase IIa study evaluating BPL-003 in patients with treatment-resistant depression (TRD). BPL-003 is its proprietary intranasal formulation of synthetic 5-MeO-DMT for treatment-resistant depression (TRD.)
“Understanding the safety, tolerability and efficacy of BPL-003 in people who are taking SSRIs is a critical step in our journey to bringing BPL-003 to market as a safe, effective and convenient treatment opportunity for both patients and providers,” stated Dr. Rob Conley, chief scientific and medical officer at Beckley Psytech. “We are looking forward to better understanding BPL-003 as an adjunctive therapy ahead of end-of-Phase II interactions with regulatory authorities, and we are thankful to the patients and study partners who …